Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 combination in HER2+ biliary tract cancer
NCT06778031Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in biliary tract cancer (BTC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Feb 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06778031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778031.